Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Hematology  |  Oncology

Search Medical Condition
Please enter condition
Please choose location from dropdown

Follicular Lymphoma Clinical Trials

A listing of Follicular Lymphoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (408) clinical trials

Open-Label Multi-Center Two-Part Ph1 Study to Characterize the PKs of an Intravenous Micro-Dose of [14C]-Tazemetostat (EPZ 6438) and the ADME of an Oral [14C]-Labeled Dose of Tazemetostat in Subjects With B-Cell Lymphomas or Adv Solid Tumors

This is a Phase 1, open-label, two-part study designed to characterize the PK of an IV dose of approximately 12 g tazemetostat that contains approximately 500 nCi of [14C] tazemetostat and the ADME of an oral dose of 800 mg tazemetostat that contains approximately 400 Ci of [14C]-labeled tazemetostat in ...

Phase

Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL

STUDY OBJECTIVES Primary Objective (Phase Ib portion of Study) To establish a safe dose (ie, number cells/m2) of ATLCAR.CD30 to infuse after lymphodepletion with bendamustine in adult patients with CD30+ refractory/relapsed Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL). To establish a safe dose (ie, number cells/m2) of ATLCAR.CD30 to infuse ...

Phase

Evaluation of Human Immune Responses to Influenza Virus Vaccination in Patients With Lymphoma

PRIMARY OBJECTIVE: I. To determine the seroprotection and seroconversion rates after influenza vaccination in patients with lymphoma receiving active treatment or in follow up observation. SECONDARY OBJECTIVES: I. To characterize influenza-specific plasmablasts and memory B cells after influenza vaccination in patients with lymphoma receiving active treatment or in follow up ...

Phase

Evaluation Study of Fear of Cancer Recurrence: Detection Measure and Risk Factors in Lymphoma Survivorship

Indeed, in a recent work published by our team, several complication types in cancer survivorship has been identified: physical but also psychosocial disorders, which can lead to quality of life deterioration. The FCR in lymphoma pathology isn't yet documented and only a few studies concern the risk factors determination (age, ...

Phase N/A

Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers

Ibrutinib is a selective oral Burton tyrosine kinase inhibitor. Through interfering with the downstream pathways of B-cell receptor signaling, it inhibits proliferation and induces apoptosis in many B-cell lymphoid malignancies. The clinical benefit of ibrutinib has been demonstrated in patients with relapsed/refractory chronic lymphocytic leukaemia, mantle cell lymphoma, small lymphocytic ...

Phase

First Line Therapy of Advanced Stage Follicular Lymphoma in Patients Not Eligible for Standard Immunochemotherapy

Study design: This is a randomized, open-label, multicenter phase III trial with a parallel-group design of two groups. Randomization and Interventions: Randomization between Obinutuzumab single agent treatment versus Obinutuzumab plus Bendamustine followed by Obinutuzumab Treatment plans: Arm A: Obinutuzumab single agent Obinutuzumab flat dose of 1000 mg on Day 1 ...

Phase

Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma

The purpose of this study is to test any good and bad effects of the study drug called ruxolitinib. Ruxolitinib works by blocking a protein called JAK. JAK works along with another protein called STAT and is important for survival of many T or NK-cell lymphomas. By blocking JAK, ruxolitinib ...

Phase

Rituximab and Pembrolizumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma

PRIMARY OBJECTIVES: I. Overall response rate (ORR) of rituximab and pembrolizumab in relapsed/refractory follicular lymphoma (FL). II. Overall response rate (ORR) of rituximab and pembrolizumab in relapsed/refractory diffuse large B cell lymphoma (DLBCL). SECONDARY OBJECTIVES: I. To evaluate the safety and tolerability of the combination of rituximab and pembrolizumab, and ...

Phase

CAR-T Treatment for Relapse / Refractory Type Safety and Effectiveness of Lymphoma

The sponsors of this research also studied CD19.CAR-T cells for the treatment of leukemia and lymphoma, two courses of three transfusion 14 days after infection process standard training program , the safety and effectiveness have accumulated some of the data. In this study, the investigators will regenerate the cultured cells ...

Phase N/A

A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas

PRIMARY OBJECTIVES: I. To estimate the maximum tolerated dose (MTD) of adoptive cellular immunotherapy using ex vivo transduced and expanded autologous T cells expressing a third (3rd)-generation fully human CD20-specific chimeric antigen receptor (CAR) in patients with relapsed or refractory CD20+ B-cell non-Hodgkin lymphoma (B-NHL). SECONDARY OBJECTIVES: I. To evaluate ...

Phase